Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study
NSAIDs in Ankylosing Spondylitis
Sponsor: Columbia University
Enrolling: Male and Female Patients
Study Length: 7 Weeks
Clinic Visits: 2
IRB Number: AAAR3505
U.S. Govt. ID: NCT03473665
Contact: Christopher Depender: 212-305-4114 /
Additional Study Information: This is a 6-week randomized, double-blind trial of 4 different non-steroidal anti-inflammatory drugs in patients with axial spondyloarthritis to compare the change of pain score from baseline at 4 weeks to the change of pain score from baseline at 6 weeks. Patients with ankylosing spondylitis or axial spondyloarthritis who fulfills the inclusion and exclusion criteria will be randomized into one of the four arms after an initial one week washout period, including: 1) indomethacin 75mg Q12H; 2) diclofenac 75mg Q12H; 3) meloxicam 7.5mg Q12H; 4) celecoxib 200mg Q12H. The treatment length will be 6 weeks. Primary outcome is the change of pain score from baseline to week 4 and to week 6.
This study is closed
Runsheng Wang, MD
Do You Qualify?
A clinical diagnosis of ankylosing spondylitis (AS) by treating rheumatologists Yes No
Are taking NSAIDs on a regular basis for AS or axSpA (defined as more than 20 days in the past month) Yes No
Concomitant anti-rheumatic drugs are allowed, if the dose has been stable for the past three months Yes No
Patients who have concurrent rheumatic diseases other than AS or axSpA Yes No
Patients who have oral corticosteroid in the past two weeks Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Christopher Depender